Cordyceps cicadae polysaccharides attenuate diabetic nephropathy via the miR ‐30a‐3p/ TRIM16 axis
Journal of Diabetes Investigation · 2024-03 · 15 (3) · 300-314
DOI: 10.1111/jdi.14116 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diabetes Investigation, online erschienen am 27.12.2023. Verfasst von Rong Zheng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Diabetes Mellitus, Type 2, MicroRNAs, Cordyceps. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Science Foundation of China, Senior Talents Program of integrated traditional Chinese and Western Medicine in Shanghai, National Natural Science Foundation of China.
Abstract (Originalsprache)
Objective
The molecular mechanism of the protective effect of Cordyceps cicadae polysaccharides (CCPs) on renal tubulointerstitial fibrosis in diabetic nephropathy (DN) is still unclear. This study aims to further understand the molecular mechanisms behind the therapeutic benefits of CCP on diabetic nephropathy.
Methods
Mice were randomly assigned into six groups ( n = 8). Cordyceps cicadae polysaccharide dissolved in 5% dimethyl sulfoxide was administered by gavage for 12 consecutive weeks. The CCP doses were divided into low, medium, and high, 75, 150, and 300 mg/kg/day, respectively. The efficacy of CCP was determined by assessing the renal function and histological alterations in diabetic db/db mice. The degree of glomerular mesangial dilatation and sclerosis was evaluated using semiquantitative markers. Cell viability, apoptosis, epithelial–mesenchymal transition (EMT), inflammation, oxidative stress, and mitochondrial reactive oxygen species (ROS) in high glucose (HG)‐cultured MPC5 podocytes were determined. The interaction of miR‐30a‐3p and tripartite motif‐containing protein 16 (TRIM16) was examined by luciferase reporter assay. Western blotting, reverse transcription‐polymerase chain reaction, and immunofluorescence were used to analyze gene and protein expressions.
Results
The in vivo findings illustrated that CCP may protect mice with type 2 diabetes from inflammation and oxidative damage ( P < 0.05). Furthermore, CCP has a therapeutic value in protecting renal function and morphology in diabetic nephropathy by reversing podocyte EMT. The in vitro results indicated that CCP dose‐dependently inhibited HG‐induced apoptosis, EMT, inflammation, oxidative stress, and mitochondrial ROS levels in MPC5 podocytes ( P < 0.05). Luciferase reporter assay confirmed the interaction between miR‐30a‐3p and TRIM16 in MPC5 podocytes cultured in high glucose ( P < 0.05).
Conclusion
The protective effect of CCP on HG‐induced MPC5 can be achieved by miR‐30a‐3p/TRIM16 axis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
ORCID-Profile: Rong Zhu
Förderung
- National Science Foundation of China
- Senior Talents Program of integrated traditional Chinese and Western Medicine in Shanghai
- National Natural Science Foundation of China
Zitieren
APA
Zheng, R., Xu, Q., Wang, Y., Zhong, Y., & Zhu, R. (2024). Cordyceps cicadae polysaccharides attenuate diabetic nephropathy via the miR ‐30a‐3p/ TRIM16 axis. Journal of Diabetes Investigation, 15(3), 300-314. https://doi.org/10.1111/jdi.14116
Vancouver
Zheng R, Xu Q, Wang Y, Zhong Y, Zhu R. Cordyceps cicadae polysaccharides attenuate diabetic nephropathy via the miR ‐30a‐3p/ TRIM16 axis. Journal of Diabetes Investigation. 2024;15(3):300-314. doi:10.1111/jdi.14116
BibTeX
@article{Zheng2024,
author = {Zheng, Rong and Xu, Qin and Wang, Yiwen and Zhong, Yifei and Zhu, Rong},
title = {Cordyceps cicadae polysaccharides attenuate diabetic nephropathy via the miR ‐30a‐3p/ TRIM16 axis},
journal = {Journal of Diabetes Investigation},
year = {2024},
volume = {15},
number = {3},
pages = {300--314},
doi = {10.1111/jdi.14116}
}
EUVIMED